Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alzheimer's disease
7
×
biogen
7
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
7
×
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
7
×
wisconsin blog main
wisconsin top stories
biotech
startups
cancer
cancer immunotherapy
deals
pfizer
bristol-myers squibb
clinical trials
eli lilly
gilead sciences
medicare
novartis
What
bio
roundup
drug
alzheimer’s
biogen
biogen’s
companies
crispr
nash
new
news
price
prices
week
acquisitions
activity
aducanumab
albert
alliance
amyloid
angst
annual
approval
approvals
assessed
attention
bagged
biggest
billions
biopharmaceutical
biotech
bourla
brammer
bristol
buy
calls
ceo
changing
clamped
color
Language
unset
unknown
Current search:
biogen
×
" national top stories "
×
" alzheimer's disease "
×
" texas top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More